ORIC Pharmaceuticals, Inc. (ORIC) Stock Score, Valuation & Financial Research

ORIC Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ORIC

ORIC Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.88. These figures are a research snapshot, not a buy or sell recommendation.

What ORIC Pharmaceuticals, Inc. does

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model relies on raising capital through equity offerings and strategic collaborations to fund the research, development, and clinical testing of its proprietary oncology drug candidates.

Products and services

  • The company is developing a pipeline of oncology therapies, including its lead clinical programs rinzimetostat (an EED inhibitor) and enozertinib (a selective EGFR inhibitor), aimed at overcoming resistance in cancer treatment.

Brands and product families

  • Rinzimetostat — Lead clinical-stage drug candidate for mCRPC. Source
  • Enozertinib — Lead clinical-stage drug candidate. Source

Customer types

Clinical trial patients and healthcare providers.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, data collection, and the manufacturing of drug substance and drug product for clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Mirati Therapeutics, Inc. — The company maintains a license agreement with Mirati for the development and commercialization rights to rinzimetostat. Source

Competitors and product-market comparisons

  • Biopharmaceutical and pharmaceutical companies — The company competes with various entities developing oncology therapies, including those targeting PRC2/EED and EGFR pathways. Source

Business strengths to evaluate

  • Focused pipeline of differentiated oncology candidates targeting resistance mechanisms Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ORIC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.88
Market capitalization:
1.23B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -140.35M
Free cash flow:
USD -114.08M
Cash:
USD 37.48M
Total debt:
USD 3.33M
EPS:
USD -1.35

What stands out

  • Free cash flow is USD -114.08M, negative for the stored period.
  • The balance sheet shows USD 37.48M of cash versus USD 3.33M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 34.16M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ORIC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ORIC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ORIC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ORIC to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ORIC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ORIC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.